A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) - Trial NCT06094296
Access comprehensive clinical trial information for NCT06094296 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bristol-Myers Squibb and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 196 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
Phase 2
Nov 03, 2023
Oct 10, 2027
Primary Outcome
Part 1: Number of Participants with Adverse Events (AEs),Part 1: Number of Participants with Treatment-related AEs (TRAEs),Part 1: Number of Participants with Serious AEs (SAEs),Part 1: Number of Participants with AEs Meeting Protocol-defined Dose Limiting Toxicity DLT Criteria,Part 1: Number of Participants with AEs Leading to Discontinuation,Part 1: Number of Participants with AEs Leading to Death,Part 2: Objective Response Rate (ORR)
Summary
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab
 in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in
 combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell
 lung cancer (NSCLC).
Data Source
ClinicalTrials.gov
NCT06094296
Non-Device Trial